The Medicine Maker / Issues / 2018 / Articles / Nov

Nov

Manufacture Vaccines Small Molecules Small Molecules

A Winning Bid

November 14, 2018

Founded in 1998, Emergent BioSolutions has gone on to become a multinational biopharma company – despite working in some difficult therapeutic areas, including biodefense.

0 min read

A Winning Bid
Manufacture Vaccines

The Intersection of Infection and Biodefense

November 14, 2018

Marcus Horwitz’s primary focus is on infectious diseases, but a number of pathogens he has studied led him into the realm of bioterrorism. Recently, Horwitz and his team has developed a single vector vaccine platform that could offer protection against tularemia, anthrax, plague, and melioidosis – all considered significant bioterrorism threats.

0 min read

The Intersection of Infection and Biodefense
Manufacture Vaccines

Rising to the Challenge

November 14, 2018

Biodefense is not just about offering protection from bioterror attacks; it’s also about being prepared for emerging infectious diseases.

0 min read

Rising to the Challenge
Business & Regulation Business Practice Trends & Forecasts Business & Trends

The Winning Strategy for Start-Ups

November 14, 2018

Business academics have been trying to uncover empirical evidence around how financing decisions are linked with technology. After all, the business of making biopharmaceuticals is expensive – so the more data you have to back up decisions, the better.

0 min read

The Winning Strategy for Start-Ups

Recommended

Browse by Topics

Interview Drug Discovery Development & Clinical Formulation Drug Delivery Bioprocessing Small Molecules Cell & Gene Facilities & Equipment Outsourcing Packaging Supply Chain Regulation & Standards Industry News Research News Sitting Down With Innovation Awards Business & Trends Technology & Manufacturing Biopharma Future of Pharma Latest Blog